School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan 250101, Shandong Province, China.
Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan 250117, Shandong Province, China.
World J Gastroenterol. 2017 Nov 7;23(41):7478-7488. doi: 10.3748/wjg.v23.i41.7478.
Chemotherapy has limited efficacy in the treatment of advanced and metastatic pancreatic cancer (PC), and has serious side effects. The development of novel effective agents, especially targeted therapy, is essential for patients with PC. We present a 58-year-old Chinese woman initially diagnosed with locally advanced PC. As the disease progressed to Stage IV, the patient was unable to tolerate chemotherapy after the fourth-line treatment. She was then treated with apatinib, a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 and achieved a progression-free-survival of 7 mo. All drug-related side effects were well controlled with medication. To the best of our knowledge, this is the first case of PC which responded to apatinib. Considering this remarkable response, apatinib may be a promising agent in the treatment of PC. We also reviewed the literature on chemotherapy and targeted therapy, especially the anti-angiogenesis therapy for patients with PC, and investigated the effect of apatinib in other solid tumors as well.
化疗在治疗晚期和转移性胰腺癌（PC）方面疗效有限，且具有严重的副作用。因此，开发新型有效的药物，尤其是靶向治疗药物，对于 PC 患者至关重要。我们报告了一例最初诊断为局部晚期 PC 的 58 岁中国女性患者。当疾病进展到 IV 期时，该患者在四线治疗后无法耐受化疗。随后，她接受了新型、高度选择性的血管内皮生长因子受体-2 酪氨酸激酶抑制剂阿帕替尼治疗，无进展生存期达到 7 个月。所有药物相关的副作用均通过药物治疗得到良好控制。据我们所知，这是首例对阿帕替尼有反应的 PC 病例。鉴于这种显著的疗效，阿帕替尼可能是治疗 PC 的一种有前途的药物。我们还回顾了化疗和靶向治疗，特别是针对 PC 患者的抗血管生成治疗的文献，并研究了阿帕替尼在其他实体肿瘤中的疗效。
